New approaches to acute lymphoblastic leukemia in adults: Where do we go?

Seminars in Oncology

Volumn 27, Issue 5, 2000, Pages 540-559

  Hoelzer, D ^a   Gokbuget, N ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOSTATIC AGENT; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TOPOTECAN; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CLINICAL PROTOCOL; CONFERENCE PAPER; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; LEUKEMOGENESIS; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; DRUG RESISTANCE, NEOPLASM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA, LYMPHOCYTIC, ACUTE; NEOPLASM, RESIDUAL; PROGNOSIS; RISK;

EID: 0033786192     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (132)

1. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study
2. Cytarabine with high-dose mitoxantrone induces rapid complete remission in adult acute lymphoblastic leukemia without the use of vincristine or prednisone
3. High dose ara-c as upfront therapy for adult patients with acute lymphoblastic leukemia (ALL)
4. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia
5. Cerebellar toxicity following hyper-CVAD regimen for acute lymphoblastic leukemia
6. Rapid remission induction therapy in adult acute lymphoblastic leukemia (ALL) without vincristine or prednisone
7. Adult acute lymphocytic leukemia: The Eastern Cooperative Oncology Group experience
8. Treatment of adult acute lymphoblastic leukaemia (ALL) over a 16 year period
9. High-dose Ara-C for remission induction and consolidation of previously untreated adults with ALL or lymphoblastic lymphoma
10. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia
11. Addition of etoposide to initial therapy of adult acute lymphoblastic leukemia: A combined clincal and laboratory study
12. A new therapeutic strategy in adult acute lymphoblastic leukemia: Intensive induction/consolidation, early transplant, maintenance-type therapy in relapse only
13. The role of anthracyclines in adult acute lymphoblastic leukemia
14. Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin
15. Nation-wide randomized comparative study of doxorubicin, vincristine and prednisolone combination therapy with and without L-asparaginase for adult acute lymphoblastic leukemia
16. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia
17. PEG L-asparaginase (PEG-ASNase) containing chemotherapy in untreated acute lymphoblastic leukemia adults
18. Toxicity and pharmacokinetics of PEG-asparaginase (PEG-asp) in newly diagnosed adult acute lymphoblastic leukemia (ALL): CALGB 9511
19. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia
20. Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia
21. Differences in cerebrospinal fluid penetration of corticosteroids: Possible relationship to the prevention of meningeal leukemia
22. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia
23. Improved results of an intensified therapy in adult acute lymphocytic leukemia
24. Results of Medical Research Council trial UKALL IX in acute lymphoblastic leukaemia in adults: Report from the Medical Research Council Working Party on Adult Leukaemia
25. Intensification of treatment for adults with acute lymphoblastic leukaemia: Results of U.K. Medical Research council randomized trial UKALL XA
26. Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: A CALGB study
27. Intensive induction/consolidation therapy without maintenance in adult acute lymphoblastic leukaemia: A pilot assessment
28. Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia
29. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia
30. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: A follow-up report
31. The GIMEMA ALL 0183 trial: Analysis of 10-year follow-up
32. Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter trial (PETHEMA ALL-89)
33. Adult acute lymphoblastic leukemia (ALL): Results of the Gimema ALL 0288 trial
34. The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: A prospective randomized clinical trial by Cancer and Leukemia Group B
35. Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84). German Adult ALL Study Group
36. Adult acute lymphoblastic leukemia: A multicentric randomized trial testing bone marrow transplantation as postremission therapy
37. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811
38. Improved outcome of adult acute lymphoblastic leukaemia by moderately intensified chemotherapy which includes a 'preinduction' course for rapid tumour reduction: Preliminary results on 66 patients
39. Intensified and shortened chemotherapy for adult acute lymphoblastic leukemia
40. Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia
41. The role of idarubicin in adult acute lymphoblastic leukaemia: From drug resistance studies to clinical application
42. Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF)
43. FLAG (fludarabine, cytarabine, G-CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: In vitro and in vivo effects
44. FLAG-Idarubicine and allogeneic stem cell transplantation for Ph-positive ALL beyond first remission
45. Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG
46. 2-Amino-9-B-D-arabinosyl-6-methoxy-9H-guanine (GW506U; Compound 506U) is highly active in patients with T-cell malignancies: Results of a phase I trial in pediatric and adult patients with refractory hematological malignancies
47. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia
48. Phase I study of topotecan, a new topoisomerase I inhibitor in patients with refractory or relapsed acute leukemia
49. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia
50. A phase II 'window' study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia
51. A phase I and pharmacodynamic study of sequential topotecan and etoposide (TE) in adult patients with refractory/relapsed acute leukemia (RAL)
52. Arsenic trioxide: Rediscovery of a tumor cell-specific agent for the treatment of Ph+ leukemia
53. Novel anti-bcr-abl strategy consisting of arsenic trioxide and CGP57148B lowers bcr-abl levels and tyrosine kinase activity resulting in apoptosis and differentiation of bcr-abl positive human leukemia cells
54. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
55. Effects of an abl-protein kinase inhibitor on the growth of BCR-ABL positive lymphoblastic leukemias in vitro
56. Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
57. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody
58. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases
59. B34(Anti-CD19)-Genistein treatment of therapy refractory B-lineage acute lymphoblastic leukemia
60. Phase I study of B43-PAP immunotoxin in combination with standard 4-drug induction for patients with CD19+ acute lymphoblastic leukemia (ALL) in relapse. A Children's Cancer Group Study
61. Anti-B4-blocked ricin as consolidation therapy for patients with B-lineage acute lymphoblastic leukemia (ALL): A phase II trial (CALGB 9311)
62. The effect of anti-B4-blocked Ricin (anti-B4-BR) on minimal residual disease (MRD) in adults with B-lineage acute lymphoblastic leukemia (ALL) (CALGB 9311,8762,8763)
63. Treatment of acute lymphoblastic leukemia (ALL) with Campath-1H: Initial observations
64. Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies
65. Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin
66. Dose-intensive therapy for adult acute lymphoblastic leukemia
67. Long term results of a prospective Belgium French protocol of treatment for adult acute lymphoblastic leukemia (ALL): LALA87 study
68. Consolidation treatment of adult acute lymphoblastic leukemia: A prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin- 2 after autologous bone marrow transplantation
69. Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL) in first complete remission (CR): Early results from the international ALL trial (MRC UKALL/ECOG E2993)
70. Bone marrow transplantation from unrelated donors for adult patients with poor-risk acute lymphoblastic leukemia: A report from the National Marrow Donor Programme (NMDP)
71. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia
72. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis
73. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia
74. The use of radiolabeled anti-CD 33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia
75. 131I-anti-CD45 antibody plus busulfan/cyclophosphamide in matched related transplants for AML in first remission
76. 188Re-labelled anti-CD164b monoclonal antibody: Results of feasibility study
77. 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome
78. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic disorders
79. Analysis of the Acute Leukemia EBMT Registry
80. Induction-consolidation with an idarubicin-containing regimen, unpurged marrow autograft, and post-graft chemotherapy in adult acute lymphoblastic leukaemia
81. Purging of peripheral blood stem cells yields BCR-ABL-negative autografts in patients with BCR-ABL-positive acute lymphoblastic leukemia
82. Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: Comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chaln reaction
83. Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow transplantation
84. Autologous bone marrow transplantation for high risk acute lymphoblastic leukemia: Clinical relevance of ex vivo bone marrow purging with monoclonal antibodies and complement
85. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia (AL) in first complete remission
86. Autologous bone marrow transplantation or peripheral blood stem cell transplantation followed by maintenance chemotherapy for adult acute lymphoblastic leukemia in first remission: 50 cases from a single center
87. Akute lymphatische Leukamie des Erwachsenen
88. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8364
89. Are 'early' and 'late' T-acute lymphoblastic leukemias different diseases? A single center study of 34 patients
90. Prethymic phenotype and genotype of pre-T(CD+/ER-)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia
91. Characteristics, outcome and risk factors in adult T-lineage acute lymphoblastic leukemia (ALL)
92. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults
93. Prepre-B acute lymphoblastic leukemia: High frequency of alternatively spliced ALL1-AF4 transcripts and absence of minimal residual disease during complete remission
94. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia - Implication for treatment of infants
95. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: Results of the German multicenter trials GMALL 03/87 and 04/89
96. Improved outcome in adult B-cell acute lymphoblastic leukemia
97. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia
98. Prospective karyotype analysis in adult acute lymphoblastic leukemia: The Cancer and Leukemia Group B experience
99. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALLL XA
100. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: Correlations with hematologic findings and outcome. A collaborative study of the Groupe Francais de Cytogenetique Hematologique
101. Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: A Pediatric Oncology Group study
102. The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia
103. High incidence of p16 deletion in adult acute lymphoblastic leukemia (ALL): Correlation with clinical features and response to treatment. CALGB 8762
104. Tumor suppression gene alteration in adult acute lyphoblastic leukemia (ALL). Analysis of retinoblastoma (Rb) and p53 gene expression in lymphoblasts of patients with de novo, relapsed, or refractory ALL treated in Southwest Oncology Group studies
105. Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia
106. Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: A Children's Cancer Group study
107. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
108. Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission
109. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: Results of an in vitro study
110. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia
111. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia
112. In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06- 97
113. The Philadelphia chromosome t(9;22) is associated with in vitro prednisolone and daunorubicin resistance in adult acute lymphoblastic leukemia
114. Biological and clinical significance of in vitro prednisolone resistance in adult acute lymphoblastic leukaemia
115. Detection of minimal residual disease in acute leukemia: Methodological advances and clinical significance
116. Immunophenotypic analysis in the monitoring of minimal residual disease
117. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction
118. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia
119. Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood
120. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia
121. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia
122. Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response
123. The effect of late intensification of therapy in children with acute lymphoblastic leukaemia and minimal residual disease
124. Investigation of minimal residual disease (MRD) in adult acute lymphoblastic leukemia: PCR tests show statistically significant value in predicting clinical outcome
125. Concordance of MRD results in matched bone marrow and peripheral blood samples indicate that peripheral blood could be a sole sample source for MRD detection in pediatric acute lymphoblastic leukemia
126. The immunological detection of minimal residual disease in acute leukemia
127. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction
128. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease
129. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia
130. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia
131. Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: Detection in remission marrow predicts outcome